BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23670521)

  • 41. Usefulness of
    López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
    Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.
    Krause BJ; Souvatzoglou M; Tuncel M; Herrmann K; Buck AK; Praus C; Schuster T; Geinitz H; Treiber U; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):18-23. PubMed ID: 17891394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study.
    Ceci F; Schiavina R; Castellucci P; Brunocilla E; Fuccio C; Colletti PM; Ferretti A; Chondrogiannis S; Rubello D; Romagnoli D; Malizia C; Martorana G; Fanti S
    Clin Nucl Med; 2013 Jul; 38(7):e279-82. PubMed ID: 23698461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
    Rinnab L; Mottaghy FM; Blumstein NM; Reske SN; Hautmann RE; Hohl K; Möller P; Wiegel T; Kuefer R; Gschwend JE
    BJU Int; 2007 Oct; 100(4):786-93. PubMed ID: 17822459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.
    Soyka JD; Muster MA; Schmid DT; Seifert B; Schick U; Miralbell R; Jorcano S; Zaugg K; Seifert HH; Veit-Haibach P; Strobel K; Schaefer NG; Husarik DB; Hany TF
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):936-43. PubMed ID: 22415598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
    Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
    World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
    Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
    Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
    Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
    Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
    Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
    Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
    Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy.
    Winter A; Uphoff J; Henke RP; Wawroschek F
    Urol Int; 2010; 84(4):418-23. PubMed ID: 20299773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Garg I; Nathan MA; Packard AT; Kwon ED; Larson NB; Lowe V; Davis BJ; Haloi R; Mahon ML; Goenka AH
    J Cancer Res Ther; 2021; 17(2):358-365. PubMed ID: 33063697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 11C-choline PET/CT and PSA kinetics.
    Castellucci P; Picchio M
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S36-40. PubMed ID: 23579864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.
    Quero L; Vercellino L; de Kerviler E; Mongiat-Artus P; Culine S; Merlet P; Ravery V; Meria P; Desgrandchamps F; Hennequin C
    Clin Nucl Med; 2015 Nov; 40(11):e492-5. PubMed ID: 26252326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
    Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
    Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.